All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.


Efficacy of Ulinastatin-Assisted Continuous Blood Purification in Managing Severe Sepsis

Author(s): Qin Li, Yizhu Gao, Yin Liang and Yiwu Zhou*
Department of Emergency, West China Hospital, Sichuan University, Sichuan, Chengdu 610017, China

Correspondence Address:
Yiwu Zhou, Department of Emergency, West China Hospital, Sichuan University, Sichuan, Chengdu 610017, China, E-mail:

To explore the efficacy of ulinastatin-assisted continuous blood purification in treating severe sepsis. The research included 240 individuals with severe sepsis admitted between June 2022 and June 2023, randomly allocated into an observation group and a control group, with 120 cases in each group. Protective measures such as anti-infection and fluid resuscitation were implemented in both patient groups prior to continuous blood purification, aiming to safeguard organ integrity and maintain the internal physiological equilibrium. Throughout the 1 w duration of continuous treatment, the control group underwent solely continuous blood purification, whereas the observation group was administered ulinastatin via injection as an additional intervention. Upon completion of the treatment, a comparison was made between the two groups regarding clinical efficacy, treatment indicators, changes in D-dimer and procalcitonin levels, and improvement rate of clinical symptoms. The observation group exhibited a significantly higher total effective rate of treatment (92.50 %) compared to the control group (80 %). Significant differences were observed between the observation group and the control group (p<0.05) in terms of hospitalization time and duration of antibiotic treatment, with the former exhibiting shorter durations. Following the treatment, the observation group displayed significantly lower acute physiology and chronic health evaluation scores in comparison to the control group. With significant reduction, D-dimer and procalcitonin levels in the observation group were lower compared to the control group. Comparative analysis revealed remarkable differences in the improvement rate of clinical symptoms between the observation group (93.33 %) and the control group (82.50 %), with the former exhibiting a higher rate of improvement. To summarize, the application of ulinastatin is worth promoting as it can improve clinical symptoms, reduce inflammatory markers, shorten hospitalization time, reduce antibiotic usage, and enhance the overall physiological status of patients with severe sepsis.

Full-Text | PDF

Google scholar citation report
Citations : 66710

Indian Journal of Pharmaceutical Sciences received 66710 citations as per google scholar report